Shameless promotion of colleagues. Rob O'Brien will be moderating a panel on the payer perspective around industry disruption. No shortage of topics on that front to bring up, that's for sure!
read full article ›News in recent months of strategic shifts or closures at #PDT leaders highlights how tough the prescription digital therapeutics business. One of the primary reasons things are tough? There isn't a straightforward path to reimbursement by payers. As such, the subcommittee hearing scheduled for Sept. 19 is a very important step forward for #PDT businesses. It's an even bigger step forward for patients who may benefit from these new digital modalities.
read full article ›The @Real Endpoints team had so much fun participating in the latest Insight Exchange with Alex Guth and Matthew Mancuso of L.E.K. to highlight learnings from our inaugural gene therapy commercial meeting. Tune in to hear Roger Longman and Ellen Licking opine (because, you know, that soooo rarely happens. 😉)
read full article ›